[ad_1]
However, in a message to Lithuania, these pharmaceutical companies do not disclose specific future quantities of vaccines or delivery schedules, said BNS spokeswoman Aistė Šuksta, Minister of Health.
“Half an hour ago, a message was received from Pfizer’s office about the planned increase in vaccine volumes from January 25, but the manufacturer did not provide exact figures or schedules,” the minister’s spokeswoman told BNS Friday night.
At the time, BioNTech said in a press release late Friday that the two companies had put together a plan to increase production capacity in Europe and deliver “significantly more doses of vaccine in the second quarter,” which required “” certain modifications in production processes. “
“Therefore, at our office in Purse, Belgium, the delivered dose quantities will be temporarily reduced next week. We will return to normal delivery times in the European Union from the week of January 25, increasing supplies to starting the week of February 15. This will allow delivery of the full amount of committed vaccine doses in the first quarter and significantly more in the second quarter, ”says BioNTech.
The Lithuanian Ministry of Health previously confirmed that it had received word from pharmaceutical companies late Thursday night that the number of vaccines would be cut in half in the next four weeks and 54,405 doses of the vaccine would be delivered instead of 108,810 doses.
Lithuania, along with other Baltic and Nordic countries, asked the European Commission to contact BioNTech and Pfizer about a delay in the vaccine because it represents a risk to the vaccination process.
According to the ministers, company representatives announced that the quantities of vaccines to be delivered to the countries will be significantly reduced in the coming weeks, some were given a deadline of February 8, 2021 and others were not given information on the estimated delivery times.
“We believe that the concerns and the message of the ministers reached the producers,” said Buk A. Šuksta.
[ad_2]
